Üriner İnkontinans Medikal Tedavisi

Key Findings & Data:The incidence of urinary incontinence increases with age and while stress urinary incontinence is more common in younger women.

💡

Conclusion & Impact:The purpose of this paper is to give an overview on the pharmacotherapy of urinary incontinence

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Urinary incontinence is defi ned as involuntary leakage of urine. This situation may effect all age groups women and constitute serious problems that may affect the patient's daily life. Urinary incontinence is divided into sub-groups, including stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence and overactive bladder. The incidence of urinary incontinence increases with age and while stress urinary incontinence is more common in younger women. The study was conducted by comparing the data of the recent international literature on this topic. The purpose of this paper is to give an overview on the pharmacotherapy of urinary incontinence

Özet

Üriner inkontinans istemsiz idrar kaçırma olarak tanımlanır. Her yaş grubundan kadını etkileyebilen bu durum hastanın günlük yaşamında ciddi sıkıntılar meydana getirmektedir. Üriner inkontinans, stres üriner inkontinans, urge üriner inkontinans,miks üriner inkontinans ve aşırı aktif mesane olmak üzere alt gruplara ayrılır. Üriner inkontinans insidansı yaşlabirlikte artar ve stres üriner inkontinans genç kadınlarda daha sık görülür. Bu çalışma bu konuda son uluslararası literatür verileri karşılaştırılarak yapılmıştır. Bu yazının amacı üriner inkontinans medikal tedavisi hakkında genel bir bakış vermektir.

Keywords

xx

🔖

Cite This Article

BOSTANCI, M. S., ÖZDEN, S., ÜNAL, O., CEVRİOĞLU, A. S., AKDEMİR, N. (2015). Üriner İnkontinans Medikal Tedavisi. Journal of Human Rhythm, Cilt: 1 - Sayı: 3, 83–89. https://ajindex.com/articles/835885

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society. Neurourol Urodynam 2002;21:167– - Rortveit G, Hunskaar S. Urinary incontinence and age at the first and last delivery: the Norwegian HUNT/EPINCONT study. Am J Obstet Gynecol;195(2):433Y438. Urinary incontinence in women: the management of urinary incontinence in women. National Collaborating Centre for Women’s and Children’s Health. Royal College of Obstetricians and Gynaecologists, September 2013.
Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011;59(3):387-400.
McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age and Ageing 2006;35(1):16–24.
Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. International Journal of Gynaecology and Obstetrics;82(3):327–38. Shamliyan T,Wyman JF, Ramakrishnan R, et al. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med 2012;156(12):861-874.
Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543Y562. Cipullo LM, Zullo F, Cosimato C, Di Spiezio Sardo A, Troisi J, Guida M. Pharmacological treatment of urinary incontinence.Female Pelvic Med Reconstr Surg. 2014 Jul-Aug;20(4):185-202.
Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida M.Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview.Eur J Obstet Gynecol Reprod Biol. Mar;174:27-34.
Cardozo L, Hebdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder; results from a randomised, doubleblind, placebo-controlled, rising dose trial. BJU Int;102:1120–7.
Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study Group. Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol;47:376–84.
Cardozo L, Dixon A. Increased warning time with Darifenacin: a new concept in the management of urinary urgency. J Urol 2005;173:1214–8.
Siddighi S, Chuan S. Medicine used in urogynecology. In: Siddighi S, Hardesty JS, eds. Urogynecology and Female